Skip to main content

Definition and Concept of Vascular Cognitive Impairment

  • Chapter
  • First Online:
Stroke Revisited: Vascular Cognitive Impairment

Part of the book series: Stroke Revisited ((STROREV))

Abstract

Worldwide, it is estimated that approximately 35 million people had dementia in 2010. With the prevalence of this condition expected to double every 20 years, dementia remains an important public health challenge. These estimates along with the growing costs of contemporary medical care have heightened interest in this disabling and progressive condition. Alzheimer disease and vascular cognitive impairment account for almost 70% of all the dementias. These two entities were traditionally considered divergent disorders. However, autopsy studies and data obtained using state-of-the-art neuroimaging modalities demonstrate that these dementia subtypes commonly coexist in the elderly. There is substantial observational epidemiologic evidence that links vascular risk factors in midlife to Alzheimer disease in the elderly. In addition, neurodegeneration and atherosclerosis have a synergistic effect on cognitive decline. These observations have fueled the provocative idea that a substantial number of the dementia cases can be prevented by controlling traditional vascular risk factors. In this chapter, we review the epidemiology and the evolution of diagnostic criteria for dementia with special emphasis on vascular cognitive impairment. In addition, we discuss the contribution of vascular risk factors to neurodegeneration and novel strategies to prevent or delay cognitive decline.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. World Health Organization and Alzheimer’s Disease International. Dementia: a public health priority. Report of the World Health Organization. 2012. http://apps.who.int/iris/bitstream/10665/75263/1/9789241564458_eng.pdf?ua=1. Accessed 20 Sep 2017.

  2. Prince M, Comas-Herrera A, Knapp M, Guerchet M. et al. World Alzheimer Report 2016. The Global Impact of Dementia. An analysis of prevalence, incidence, cost and trends. 2017. https://www.alz.co.uk/research/WorldAlzheimerReport2016.pdf. Accessed 20 Sep 2017.

  3. Alzheimer’s Association. 2016 Alzheimer’s disease facts and figures. Alzheimers Dement. 2016;12(4):459–509.

    Article  Google Scholar 

  4. Roth DL, Fredman L, Haley WE. Informal caregiving and its impact on health: a reappraisal from population-based studies. Gerontologist. 2015;55(2):309–19.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Gorelick PB, Mangone CA. Vascular dementias in the elderly. Clin Geriatr Med. 1991;7(3):599–615.

    Article  CAS  PubMed  Google Scholar 

  6. Roth M. The natural history of mental disorder in old age. J Ment Sci. 1955;101(423):281–301.

    Article  CAS  PubMed  Google Scholar 

  7. Mayer-Gross W, Slater E, Roth M. Clinical psychiatry. In: Anonymous. 3rd ed. Baltimore: Williams and Wilkins; 1969. p. 593–69.

    Google Scholar 

  8. Hachinski VC, Lassen NA, Marshall J. Multi-infarct dementia. A cause of mental deterioration in the elderly. Lancet. 1974;2(7874):207–10.

    Article  CAS  PubMed  Google Scholar 

  9. Hachinski VC. The decline and resurgence of vascular dementia. CMAJ. 1990;142(2):107–11.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Pantoni L, Gorelick PB, editors. Cerebral small vessel disease. Cambridge: Cambridge University Press; 2014.

    Google Scholar 

  11. Hachinski V, Sposato LA. Dementia: from muddled diagnoses to treatable mechanisms. Brain. 2013;136(Pt 9):2652–4.

    Article  PubMed  Google Scholar 

  12. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43(2):250–60.

    Article  CAS  PubMed  Google Scholar 

  13. Farooq MU, Min J, Goshgarian C, et al. Pharmacotherapy for vascular cognitive impairment. CNS Drugs. 2017;31(9):759–76.

    Article  CAS  PubMed  Google Scholar 

  14. Chui HC, Victoroff JI, Margolin D, et al. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer’s Disease Diagnostic and Treatment Centers. Neurology. 1992;42(3 Pt 1):473–80.

    Article  CAS  PubMed  Google Scholar 

  15. Rosenberg GA, Wallin A, Wardlaw JM, et al. Consensus statement for diagnosis of subcortical small vessel disease. J Cereb Blood Flow Metab. 2016;36(1):6–25.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(9):2672–713.

    PubMed  PubMed Central  Google Scholar 

  17. Sachdev P, Kalaria R, O’Brien J, et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014;28(3):206–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. American Psychiatric Association, editor. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013.

    Google Scholar 

  19. Skrobot OA, O’Brien J, Black S, et al. The vascular impairment of cognition classification consensus study. Alzheimers Dement. 2017;13(6):624–33.

    Article  PubMed  Google Scholar 

  20. Gorelick PB, Furie KL, Iadecola C, et al. Defining optimal brain health in adults: a presidential advisory from the American Heart Association/American Stroke Association. Stroke. 2017;48(10):e284–303.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Jellinger KA. Pathology and pathogenesis of vascular cognitive impairment—a critical update. Front Aging Neurosci. 2013;5:17.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822–38.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Scheltens P, Blennow K, Breteler MM, et al. Alzheimer’s disease. Lancet. 2016;388(10043):505–17.

    Article  CAS  PubMed  Google Scholar 

  24. Maillard P, Mitchell GF, Himali JJ, et al. Effects of arterial stiffness on brain integrity in young adults from the Framingham Heart Study. Stroke. 2016;47(4):1030–6.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Jellinger KA. Clinicopathological analysis of dementia disorders in the elderly—an update. J Alzheimers Dis. 2006;9(3 Suppl):61–70.

    Article  PubMed  Google Scholar 

  26. Testai FD, Gorelick PB. Vascular cognitive impairment and Alzheimer disease: are these disorders linked to hypertension and other cardiovascular risk factors? In: Aiyagari V, Gorelick PB, editors. Hypertension and stroke. 2nd ed. New York: Humana Press; 2016. p. 261–84.

    Chapter  Google Scholar 

  27. Kisler K, Nelson AR, Montagne A, et al. Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. Nat Rev Neurosci. 2017;18(7):419–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Tarasoff-Conway JM, Carare RO, Osorio RS, et al. Clearance systems in the brain-implications for Alzheimer disease. Nat Rev Neurol. 2015;11(8):457–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352(9137):1347–51.

    Article  CAS  PubMed  Google Scholar 

  30. Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003;163(9):1069–75.

    Article  CAS  PubMed  Google Scholar 

  31. Iadecola C, Yaffe K, Biller J, et al. Impact of hypertension on cognitive function: a scientific statement from the American Heart Association. Hypertension. 2016;68(6):e67–94.

    Article  CAS  PubMed  Google Scholar 

  32. Launer LJ, Miller ME, Williamson JD, et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol. 2011;10(11):969–77.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Cukierman-Yaffe T, Bosch J, Diaz R, et al. Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial. Lancet Diabetes Endocrinol. 2014;2(7):562–72.

    Article  CAS  PubMed  Google Scholar 

  34. Tuligenga RH. Intensive glycaemic control and cognitive decline in patients with type 2 diabetes: a meta-analysis. Endocr Connect. 2015;4(2):R16–24.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Areosa Sastre A, Vernooij RW, Gonzalez-Colaco Harmand M, et al. Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia. Cochrane Database Syst Rev. 2017;6:CD003804.

    PubMed  Google Scholar 

  36. Reis JP, Loria CM, Launer LJ, et al. Cardiovascular health through young adulthood and cognitive functioning in midlife. Ann Neurol. 2013;73(2):170–9.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Andrieu S, Guyonnet S, Coley N, et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol. 2017;16(5):377–89.

    Article  CAS  PubMed  Google Scholar 

  38. Moll van Charante EP, Richard E, Eurelings LS, et al. Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial. Lancet. 2016;388(10046):797–805.

    Article  PubMed  Google Scholar 

  39. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255–63.

    Article  PubMed  Google Scholar 

  40. Maillard P, Mitchell GF, Himali JJ, et al. Aortic stiffness, increased white matter free water, and altered microstructural integrity: a continuum of injury. Stroke. 2017;48(6):1567–73.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Fernando D. Testai .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Science+Business Media Singapore

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Testai, F.D., Gorelick, P.B. (2020). Definition and Concept of Vascular Cognitive Impairment. In: Lee, SH., Lim, JS. (eds) Stroke Revisited: Vascular Cognitive Impairment. Stroke Revisited. Springer, Singapore. https://doi.org/10.1007/978-981-10-1433-8_1

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-1433-8_1

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-1432-1

  • Online ISBN: 978-981-10-1433-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics